Lummy Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 45.9172 million yuan
According to the Zhitong Finance APP, Lummy released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 581 million yuan, a year-on-year decrease of 4.06%. The net loss attributable to shareholders of the listed company was 45.9172 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 48.379 million yuan. The basic loss per share was 0.0435 yuan
According to the Zhitong Finance APP, Lummy (300006.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 581 million yuan, a year-on-year decrease of 4.06%. The net loss attributable to shareholders of the listed company was 45.9172 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 48.379 million yuan. The basic loss per share was 0.0435 yuan
